EPS for DexCom, Inc. (DXCM) Expected At $0.03

February 14, 2018 - By Michael Collier

 EPS for DexCom, Inc. (DXCM) Expected At $0.03
Investors sentiment decreased to 0.97 in 2017 Q3. Its down 0.39, from 1.36 in 2017Q2. It dived, as 59 investors sold DexCom, Inc. shares while 69 reduced holdings. 31 funds opened positions while 93 raised stakes. 98.30 million shares or 1.76% more from 96.59 million shares in 2017Q2 were reported.
Suntrust Banks owns 10,969 shares or 0% of their US portfolio. Alliancebernstein Ltd Partnership reported 0.04% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Bluestein R H And Co stated it has 8,725 shares or 0.02% of all its holdings. Paloma Mgmt owns 5,500 shares or 0% of their US portfolio. Morgan Stanley invested in 2.57 million shares. Granite Prtn Limited Liability Company accumulated 118,894 shares. San Francisco Sentry (Ca) has 50 shares for 0% of their portfolio. Pnc Service Gp has invested 0% in DexCom, Inc. (NASDAQ:DXCM). Sterling Capital Mgmt Lc reported 0.01% in DexCom, Inc. (NASDAQ:DXCM). Loring Wolcott And Coolidge Fiduciary Limited Liability Partnership Ma reported 8 shares. Eaton Vance Mngmt has invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Victory has 136,533 shares for 0.02% of their portfolio. 3,503 are owned by Manufacturers Life Insur Company The. Pillar Pacific Mngmt Ltd Llc has invested 0.03% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). United Capital Advisers Ltd Company reported 31,035 shares or 0.01% of all its holdings.

Since August 23, 2017, it had 0 buys, and 11 sales for $2.57 million activity. DOUBLEDAY RICHARD sold 1,635 shares worth $89,384. On Monday, September 25 Pacelli Steven Robert sold $101,219 worth of DexCom, Inc. (NASDAQ:DXCM) or 1,450 shares. GREGG TERRANCE H sold $568,588 worth of stock or 10,000 shares. SAYER KEVIN R also sold $416,044 worth of DexCom, Inc. (NASDAQ:DXCM) on Wednesday, September 20.

Analysts expect DexCom, Inc. (NASDAQ:DXCM) to report $0.03 EPS on February, 27.They anticipate $0.12 EPS change or 133.33 % from last quarter’s $-0.09 EPS. DXCM’s profit would be $2.61M giving it 455.58 P/E if the $0.03 EPS is correct. After having $-0.03 EPS previously, DexCom, Inc.’s analysts see -200.00 % EPS growth. The stock decreased 0.04% or $0.02 during the last trading session, reaching $54.67. About 572,861 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 9.41% since February 14, 2017 and is uptrending. It has underperformed by 7.29% the S&P500.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 23 analysts covering Dexcom (NASDAQ:DXCM), 16 have Buy rating, 1 Sell and 6 Hold. Therefore 70% are positive. Dexcom had 63 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Desjardins Securities given on Friday, September 16. BMO Capital Markets maintained DexCom, Inc. (NASDAQ:DXCM) rating on Wednesday, September 27. BMO Capital Markets has “Buy” rating and $62.0 target. The rating was maintained by Canaccord Genuity on Tuesday, June 6 with “Buy”. BMO Capital Markets maintained it with “Buy” rating and $74.0 target in Tuesday, December 12 report. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Jefferies on Wednesday, February 24. The firm earned “Buy” rating on Friday, August 7 by Piper Jaffray. BTIG Research upgraded DexCom, Inc. (NASDAQ:DXCM) on Monday, October 31 to “Buy” rating. The firm has “Buy” rating given on Wednesday, November 1 by BMO Capital Markets. B. Riley & Co upgraded the stock to “Buy” rating in Thursday, December 15 report. On Tuesday, August 22 the stock rating was maintained by Canaccord Genuity with “Buy”.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $4.75 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

More recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Businesswire.com which released: “Tandem Diabetes Care Announces Closing of $69 Million Underwritten Public …” on February 13, 2018. Also Streetinsider.com published the news titled: “Form SC 13G/A DEXCOM INC Filed by: BAILLIE GIFFORD & CO” on January 31, 2018. Businesswire.com‘s news article titled: “DexCom Announces Upcoming Conference Presentations” with publication date: February 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.